Key information

Recruitment dates:

29 June, 2018 to 1 October, 2020
(Trial recruitment open)

Treatment stage:

other

Trial investigator:

Dr. Marcia Hall

Mount Vernon Hospital

Northwood, Middx

HA6 2NR

Trial Coordinator: Charlotte Roberts

Charlotte.Roberts12@nhs.net

Tags:

RaNGO
rare gynaecological neoplasms

Acronym:

RaNGO

Clinical trial locations

Location list

Address:
Mount Vernon Hospital
Northwood
Middx
HA6 2NR
Address:
Royal Cornwall Hospital
Truro
TR1 3LQ

Introduction

Gynaecological cancer patients are all managed within 34 Cancer Centres located across the UK. These centres are only likely to see 1-5 new patients per year with rare gynaecological cancers. The low numbers of these cancers means that no single doctor or centre in the UK (or internationally) can hope to gain sufficient experience to be able to confidently treat patients with these specific types of cancer.  At present doctors base their treatment on discussions with more experienced colleagues, published case reports and common sense. 

About the trial

The purpose of this study is to obtain more information about specific rare gynaecological cancers. Gynaecological oncology doctors have selected approximately 20 gynaecological cancers that are very uncommon (probably between 5 and 50 new cases in the UK per year per rare cancer type). The information from the study will help doctors to better understand how these rare cancers are diagnosed and managed at present so that in the future they can be more confident about what treatments to offer patients.  

Information about the rare gynaecological cancer, and any other significant medical conditions, together with any treatments (now, and in the longer term) will be collected from the treating hospital and entered anonymously into the RaNGO database.

As it is very difficult to obtain blood or tissue samples from enough patients with rare cancers, it is hoped that patients in this study will agree to donate samples (from the biopsies or surgical procedures that they have already had for diagnosis or treatment) for future scientific research. Therefore participants will also be invited to anonymously donate tissue, blood and bodily fluid (if available) samples to RaNGO.

A RaNGO Tissue Bank has been created and is hosted at the Human Tissue Resource Centre based at St Bartholomew’s Hospital in London.  

Who can take part?

This trial is for women diagnosed with the following rare gynaecological cancers:

Ovary                              

Malignant germ cell tumours (dysgerminoma, yolk sac tumour, choriocarcinoma,

 embryonal carcinoma, immature teratoma, malignant mixed germ cell tumour,

 teratoma with secondary malignant transformation) 

 Potentially malignant non-granulosa cell sex-cord stromal tumours

 (Sertoli, Sertoli-Leydig, Leydig and steroid cell tumours; microcystic stromal tumours, sex-cord tumour with annular tubules [SCTAT])

 Small Cell Carcinoma of Ovary, Hypercalcaemic Type (Malignant

rhabdoid tumour of the ovary) 

 Adult Granulosa Cell Tumour

Juvenile Granulosa Cell Tumour

Neuroendocrine Carcinomas

Adnexa                                                                                 

Female adnexal tumour of probable Wolffian origin (FATWO)

Neuroendocrine Carcinomas

Uterus                                                                         

Endometrial stromal sarcoma, low and high-grade 

 Undifferentiated uterine sarcoma

 Leiomyosarcoma and smooth muscle tumour of uncertain

malignant potential (STUMP)

 Uterine tumour resembling ovarian sex cord tumour (UTROSCT)

Neuroendocrine Carcinomas

Cervix                                                                      

Neuroendocrine tumours (all WHO categories) 

 Unusual morphological subtypes of cervical adenocarcinoma

(gastric type, mesonephric, serous, clear cell, carcinosarcoma) 

 Adenoid basal and adenoid cystic carcinoma

 

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.